Health & Pharm General

Anatara Lifesciences Ltd (ASX:ANR) Video Interview with CEO Steven Lydeamore on Development of Human Health Product

🕔3/22/2019 1:03:12 PM

Anatara Lifesciences Ltd (ASX:ANR) CEO Steven Lydeamore, recently appointed to the company, is interviewed by ABN Newswire on the development of Irritable Bowl Syndrome (IBS) dietary supplements to address the growing need for a product that addresses the full range of IBS symptoms.

Read Full Article

MMJ Group Holdings Ltd (ASX:MMJ) Net Tangible Asset Backing - 41 Cents

🕔3/19/2019 11:57:02 AM

MMJ Group Holdings Limited (ASX:MMJ) (OTCMKTS:MMJJF) provides an update on valuation of its investment portfolio.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) PAC Partners Equity Research Report

🕔3/19/2019 9:29:24 AM

PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Pitt Street Research Report

🕔3/19/2019 9:13:38 AM

Pitt Street Research has released its latest initiating research and valuation report on Anatara Lifesciences (ASX:ANR). The report provides a $1.34 per share base case and a $3.61 optimistic case using a probability-weighted DCF valuation approach.

Read Full Article

MMJ Group Holdings Ltd (ASX:MMJ) Net Tangible Asset Backing

🕔3/14/2019 3:03:36 PM

MMJ Group Holdings Limited (ASX:MMJ) (OTCMKTS:MMJJF) provides an update on valuation of its investment portfolio.

Read Full Article

MMJ Group Holdings Ltd (ASX:MMJ) Portfolio Update

🕔3/5/2019 2:29:28 PM

MMJ Group Holdings Limited (ASX:MMJ) (OTCMKTS:MMJJF) provides an update on recent events in the MMJ investment portfolio.

Read Full Article

Regeneus Ltd (ASX:RGS) Half-Year Report

🕔3/1/2019 8:08:49 AM

Regeneus (ASX:RGS) is an ASX-listed clinical-stage regenerative medicine company developing a portfolio of novel cell-based therapies targeting significant unmet medical needs in human and animal health, with an initial focus on osteoarthritis, neuropathic pain and dermatology. The Company's product pipeline is underpinned by proprietary stem cell technologies.

Read Full Article